英文摘要 |
Background: Previous studies have revealed that the Cobas® EGFR Mutation Test v2 kit can detect epidermal growth factor receptor (EGFR) mutation in cerebrospinal fluid (CSF); however, the sample validity and quality have not yet been evaluated. Therefore, clinical methods and improved sample processing are required to improve EGFR mutation analysis using CSF samples. Materials and Methods: We obtained CSF cytological examination and EGFR mutation analysis results of 22 patients with brain or leptomeningeal metastases due to lung adenocarcinoma. Results: Compared to patients without leptomeningeal metastasis, those with leptomeningeal metastasis had significantly increased sample validity and EGFR mutation detection rates when CSF supernatant was used for mutation analysis (28.6% vs. 71.4%, P = 0.024 by Fisher’s exact test). In contrast, neither brain metastases nor cytological results were substantially associated with the sample validity or the EGFR detection rate. In 11 patients with invalid CSF supernatant, 4 patients had valid extracted DNA samples from CSF pellets. Of these 4, 3 had detectable EGFR mutation alleles. Conclusion: Our study demonstrates the capability of the Cobas® EGFR Mutation Test v2 kit for detecting EGFR mutations in CSF samples and provides insights into sample selection and processing required for this kit. |